share_log

MangoRx Acquires Patent Portfolio For Total Of $20M Through Issuance Of 980K Of 6% Series C Convertible Preferred Shares

Benzinga ·  Apr 25 08:34

Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair

Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that it has acquired a global patent portfolio for a pioneering oral solution and application aimed to combat and prevent a spectrum of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the "Patent Portfolio") from Intramont Technologies, Inc. ("Intramont"), pursuant to a Patent Purchase Agreement ("PPA").

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment